AI for Drug Discovery & Development Header Image

 





AI for Drug Discovery & Development
Accelerate Therapeutic Discovery, Design, Validation, and Development with AI
5/19/2027 - May 20, 2027 ALL TIMES EDT
The AI for Drug Discovery & Development track explores how AI is transforming the discovery and advancement of new therapeutics. Topics include target and biomarker discovery, foundation models, molecular and therapeutic design, predictive modeling, medicinal chemistry, agentic workflows, and AI-integrated experimentation. Through real-world applications, attendees will learn how these approaches expand biological and chemical exploration, prioritize promising targets and candidates, connect computational predictions with experimental validation, accelerate design-make-test-learn cycles, improve R&D decision-making, and advance promising therapies more efficiently from discovery toward development.
Preliminary Agenda

AGENTIC AI & AUTOMATED WORKFLOWS FOR DRUG DISCOVERY

Orchestrated Molecular Discovery: AI-Driven Library Design and Laboratory Automation

Brian Claus, Executive Director, RBI&T Molecular Design Technologies, Bristol Myers Squibb Co. , Executive Director, RBI&T Molecular Design Technologies , Bristol Myers Squibb Co

Orchestrated Molecular Discovery links design, synthesis, testing and analysis into a closed Design-Make-Test-Analyze loop. An agentic library designer selects reagents and compounds against explicit, testable hypotheses. It scores each hypothesis by hit rate as assay results return and ranks hypotheses for the next round. It records its rationale so chemists can challenge or override it. The informatics loop is closed and in use across active programs; automated synthesis and testing come next.

FEDERATED AI FOR DRUG DISCOVERY: FROM COLLABORATIVE LEARNING TO THERAPEUTIC DESIGN

Accelerating Drug Discovery with Federated Learning: Inside Lilly TuneLab

Photo of Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company , Sr. Director - Ecosystem Growth and Contributor Partnerships , Eli Lilly and Company
Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company , Sr. Director - Ecosystem Growth and Contributor Partnerships , Eli Lilly and Company

We will discuss how federated learning supports model improvement with privacy preserving methods. We will share how we are building trust in AI/ML models through explainability and discuss lessons and case studies from scaling the platform with over 150 participating companies around the world.

Designing Immune Therapies for Antigen Escape

Photo of Alireza Daneshvar, Co-Founder & CEO, Pioneera Biosciences , Co-Founder & CEO , Pioneera Biosciences
Alireza Daneshvar, Co-Founder & CEO, Pioneera Biosciences , Co-Founder & CEO , Pioneera Biosciences

Antigen escape is a therapeutic-design challenge that connects target selection, molecular optimization and construct engineering. This session examines how computational design can be linked to experimental validation, separating promising predictions from evidence that supports a development decision. The discussion focuses on immune-therapy design principles and their limits, without treating different therapeutic modalities as interchangeable.

AI-DRIVEN THERAPEUTIC DESIGN & EXPERIMENTAL VALIDATION

Designing Regeneration: How AI Could Help Medicine Shift from Managing Decline to Restoring Biology

Sean McClain, Founder & CEO, Absci Corp. , Founder & CEO , Absci Corp

What if the next era of drug discovery is not simply about slowing disease, but helping the body recover biological functions it already knows how to perform? This talk will explore the emerging intersection of generative AI and regenerative medicine: how AI could help scientists identify biological “switches,” design highly specific medicines around them, and pursue therapies intended to move beyond symptom management toward restoring healthy biology.

Bridging the Translational Gap: From AI-Driven Drug Discovery to Human Biology

Lei Xie, PhD, Professor, Pharmaceutical & Biomedical Sciences, Northeastern University; Adjunct Profession, Computer Science, The City University of New York; CSO, Dark Matter Therapeutics, Inc. , Prof , Pharmaceutical & Biomedical Sciences , Northeastern Univ

AI has transformed early drug discovery, yet predicting how new therapeutics will behave in humans remains a critical challenge. Bridging this translational gap requires moving beyond molecular predictions toward AI models grounded in physics, human biology, and physiology. This presentation explores emerging first-principles AI approaches, including physics-informed virtual cells, and their potential to improve predictions of drug response and inform therapeutic development decisions.

From Public Fc Mutational Data to Experiment-Ready Designs: A Calibrated AI-Assisted Workflow for Multi-Receptor Fc Engineering

Photo of MengWei Kuo, PhD, Executive Director, CMC & AI Enabled Development, HanchorBio, Inc. , Exec Dir CMC & AI Enabled Dev , CMC & AI Enabled Dev , HanchorBio Inc
MengWei Kuo, PhD, Executive Director, CMC & AI Enabled Development, HanchorBio, Inc. , Exec Dir CMC & AI Enabled Dev , CMC & AI Enabled Dev , HanchorBio Inc

Public Fc mutational datasets provide broad interaction landscapes, but affinity alone is not a design decision. We built an AI-assisted workflow that calibrates public DMS data against internal receptor-response measurements to define multi-receptor design windows. Following calibration, an initial 187-candidate public-data shortlist was refined to a final 37-candidate set; approximately 7~10 candidates entered only after calibration. The resulting set informed a focused prospective PoC panel for validation.

CONNECTING MOLECULAR & CLINICAL EVIDENCE FOR AI-DRIVEN DRUG DEVELOPMENT

Unblinding Clinical Trial Data for AI: Connecting Molecular Structures, Patents, and Clinical Evidence

Photo of Christopher Southan, PhD, Honorary Professor, Deanery of Biomedical Sciences, University of Edinburgh , Honorary Professor, Deanery of Biomedical Sciences , University of Edinburgh
Christopher Southan, PhD, Honorary Professor, Deanery of Biomedical Sciences, University of Edinburgh , Honorary Professor, Deanery of Biomedical Sciences , University of Edinburgh

A major problem with clinical trial data is that interventions are often specified only by proprietary code names rather than chemical structures of administered compounds or the squences of biologics.  The extent of this blinding is 84% at Phase I,  58% at Phase II and still 33% at Phase III. This presentation explores ways of unblinding using LLMs and manual curation for recent Alzheimer interventions in clilicaltrrials.gov. Perplexity AI provided context on code names but could not usually resolve the structures. Manual curation was effective for tracking back interventions to their patents. Even where the lead structure could not be identified the patent often included SAR data from the same chemical series. For antibodies and other biologics the sequences were often disclosed in the patents. Thus even partial unblinding felicitates new insights via CDISC and  AI analysis including pre-clinical to clinical data integration.

THE FUTURE OF SCIENTIFIC DISCOVERY: HUMAN JUDGMENT AND AI-DRIVEN R&D

PLENARY KEYNOTE PRESENTATION: When AI Becomes the Scientist's Partner: Human Judgment and the Future of R&D

Photo of Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Photo of Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck
Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck

As AI agents evolve from research assistants into active partners in scientific discovery, what becomes the scientist's unique contribution? How can researchers challenge AI-generated conclusions, recognize overlooked opportunities, and preserve scientific judgment? Senior biopharma leaders will explore how human-AI collaboration is transforming R&D decision-making, operating models, workforce capabilities, and accountability, while examining the leadership and organizational strategies needed to harness increasingly autonomous AI systems for scientific innovation and patient impact.

CHANGING THE TRAJECTORY OF DISEASE: FROM PREDICTION TO INTERVENTION

PLENARY KEYNOTE PRESENTATION: Can we Predict Disease before it Happens? Mapping and Redirecting Biological Trajectories

Photo of John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago
John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago

Biomedical research has generated increasingly large, rich, and multidimensional datasets, yet we still often study disease by dividing people into discrete categories: healthy or diseased, responder or non-responder, case or control. Biology, however, does not operate in static states. Disease develops along a continuum, shaped by changing regulatory programs and influenced by aging, biological sex, genetics, epigenetics, and environmental exposures.

As our data and computational capabilities advance, an important opportunity is emerging: moving beyond cataloging molecular differences to reconstructing how biological systems change over time. Gene regulatory networks, pseudo-time modeling, and change-point analysis can help identify critical regulatory switches that move a biological system from one state to another and reveal drivers of disease that may be missed when we focus only on individual mutations, genes, or biomarkers.

These approaches are beginning to provide insight into why individuals exposed to similar risks can follow very different disease trajectories, why biological sex can influence disease susceptibility and treatment response, and how aging may reshape the path toward chronic disease. Identifying these transition points may also uncover new therapeutic targets and opportunities to intervene before disease becomes firmly established.

The ultimate vision is a predictive theoretical biology: The ability to understand where an individual is biologically, anticipate where that trajectory may lead, and identify opportunities to redirect it. Moving from describing disease after it occurs toward predicting and ultimately altering its course could transform how we approach target discovery, therapeutic development, and precision medicine.

PLENARY KEYNOTE PRESENTATION: From Data to the Individual: Connecting the Pieces to Deliver Precision Medicine

Photo of Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham
Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham

Delivering precision medicine requires more than sophisticated technologies or increasingly complex datasets. Understanding individual patients, particularly those with complex diseases and post-infectious syndromes, demands integration of genomic, molecular, clinical, environmental, and longitudinal information. This presentation explores how connecting fragmented expertise, data, and computational capabilities can bridge the gaps between discovery, biological understanding, and clinical action, advancing a more collaborative, integrated approach to individualized diagnosis and treatment.


Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure